Developing a dedicated dermatology service for allogeneic bone marrow transplant recipients
Main Authors: | Danby, R, Matin, R, Gibbons, E, Venning, V, Rowly, L, Barton, D, Pawson, R, Littlewood, T, Reed, J, Peniket, A |
---|---|
Format: | Journal article |
Published: |
Wiley
2017
|
Similar Items
-
Analysis of factors affecting outcome in recipients of bone marrow transplantation for myelodysplasia; a single centre's experience over a nine year period
by: Stoll, V, et al.
Published: (2010) -
CONCENTRATIONS OF IgG SUBCLASSES IN ALLOGENEIC BONE MARROW RECIPIENTS
by: A. V. Klimovich, et al.
Published: (2014-07-01) -
Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.
by: Medd, P, et al.
Published: (2011) -
Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant
by: Medd, P, et al.
Published: (2011) -
DONOR’S BONE MARROW CELLS AS REGULATORS OF IMMUNE TOLERANCE INDUCTION IN RECIPIENT’S OF ALLOGENIC ORGANS
by: N. A. Onishchenko, et al.
Published: (2009-06-01)